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Abstract
In September 2013, the Hawaii Department of Health (HDOH) was notified of seven adults who 
developed acute hepatitis after taking OxyELITE Pro™, a weight loss and sports dietary 
supplement. CDC assisted HDOH with their investigation, then conducted case-finding outside of 
Hawaii with FDA and the Department of Defense (DoD).
We defined cases as acute hepatitis of unknown etiology that occurred from April 1, 2013, through 
December 5, 2013, following exposure to a weight loss or muscle-building dietary supplement, 
such as OxyELITE Pro™. We conducted case-finding through multiple sources, including data 
from poison centers (National Poison Data System [NPDS]) and FDA MedWatch.
We identified 40 case-patients in 23 states and two military bases with acute hepatitis of unknown 
etiology and exposure to a weight loss or muscle building dietary supplement. Of 35 case-patients 
who reported their race, 15 (42.9%) reported white and 9 (25.7%) reported Asian. Commonly 
reported symptoms included jaundice, fatigue, and dark urine. Twenty-five (62.5%) case-patients 
reported taking OxyELITE Pro™. Of these 25 patients, 17 of 22 (77.3%) with available data were 
hospitalized and 1 received a liver transplant. NPDS and FDA MedWatch each captured seven 
(17.5%) case-patients.
Improving the ability to search surveillance systems like NPDS and FDA MedWatch for individual 
and grouped dietary supplements, as well as coordinating case-finding with DoD, may benefit 
ongoing surveillance efforts and future outbreak responses involving adverse health effects from 
dietary supplements. This investigation highlights opportunities and challenges in using multiple 
sources to identify cases of suspected supplement associated adverse events. Published 2016. This 
article is a U.S. Government work and is in the public domain in the USA.
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Introduction
Dietary supplements are commonly used in the United States.[1,2] Some populations, such as 
military personnel, are more likely to use certain types of dietary supplements, such as 
weight loss or sports supplements, than the general population.[3] Some of these dietary 
supplements, particularly herbal products and those used for performance enhancement, 
have been associated with liver injury.[4–6] No comprehensive surveillance system is 
available for dietary supplement-induced liver injury, so information regarding supplement-
induced liver injury comes from case reports and series, outbreak investigations, prospective 
registries, and voluntary reporting to FDA MedWatch and poison centers.[7]
On September 9, 2013, clinicians at a single tertiary care hospital in Hawaii notified the 
Hawaii Department of Health (HDOH) of seven patients who presented with severe acute 
hepatitis and fulminant liver failure of unknown etiology.[8] Abnormal laboratory findings 
included markedly elevated liver enzymes (aspartate aminotransferase [AST] and alanine 
aminotransferase [ALT]), as well as total bilirubin. Testing for infectious agents, including 
hepatitis serologies, was negative; however, clinicians noted that all seven patients consumed 
OxyELITE Pro™, a weight loss or sports dietary supplement. On September 27, 2013, staff 
from the U.S. Centers for Disease Control and Prevention (CDC) joined HDOH to assist 
with their investigation. Case-finding efforts in Hawaii identified 52 case-patients with acute 
hepatitis of unknown etiology who had ingested a dietary supplement during the 60 days 
prior to illness onset. These case-patients, the majority of whom consumed OxyELITE 
Pro™, are described elsewhere.[9] Based on the preliminary findings from the Hawaii 
investigation, the U.S. Food and Drug Administration (FDA) initiated an investigation into 
the manufacture and distribution of OxyELITE Pro™. Case-patients reported using 
OxyELITE Pro™ products from multiple lots, and a trace back investigation found each of 
these lots was distributed to states in addition to Hawaii. Due to the nationwide distribution 
of OxyELITE Pro™, CDC, in collaboration with FDA and U.S. Department of Defense 
(DoD), initiated case-finding in the United States outside of Hawaii for additional cases of 
acute hepatitis of unknown etiology and exposure to a weight loss or muscle building dietary 
supplement. This manuscript describes the different sources through which we identified 
suspected case-patients and summarizes the presenting signs and symptoms, exposures, and 
laboratory data from these case-patients.
Methods
We defined a case as acute hepatitis of unknown etiology that developed between April 1, 
2013, and December 5, 2013, in a non-Hawaii resident who consumed a dietary supplement 
marketed for weight loss or muscle building in the 60 days prior to illness onset. Case-
patients had 1) an ALT value ≥ four times the upper limit of normal (approximately 160 
international units per liter, IU/L); 2) a total bilirubin level ≥ two times the upper limit of 
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normal (approximately 2.5 milligrams per deciliter, mg/dL); 3) a negative viral hepatitis 
panel; 4) hepatic imaging (i.e., ultrasound, CT scan, MRI) not consistent with alternative 
etiologies of non-viral hepatitis (e.g., cholelithiasis); 5) no recent hypotensive shock or 
septic episodes; 6) no pre-existing diagnosis of a chronic liver disease such as autoimmune 
hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, Wilson’s disease, or 
hemochromatosis; and 7) no chronic alcohol abuse documented in their medical record. The 
only difference between our case definition and the one used in the Hawaii investigation was 
that we restricted our case definition to non-Hawaii residents.[9] We used four distinct 
approaches to identify potential cases —National Poison Data System (NPDS), FDA 
MedWatch, a national call for cases, and DoD case finding. Case-finding from NPDS and 
FDA MedWatch was restricted to cases involving OxyELITE Pro™. Below are descriptions 
of the four approaches used.
1. NPDS — NPDS collects information from all calls received by U.S. poison 
centers.[10] When an individual or healthcare provider calls to report an exposure 
to a product, poison center staff collects information on the exposure and assigns 
a unique, product-specific numerical code for the exposure. Since dietary 
supplements are coded individually and no product code encompasses all dietary 
supplements, we included calls involving only the product code for OxyELITE 
Pro™. We retrospectively searched NPDS for all calls received between April 1, 
2013, and September 25, 2013, in which a caller reported an exposure to 
OxyELITE Pro™ and had an elevated ALT or total bilirubin. We selected April 
1, 2013, based on the earliest exposure among the initial seven patients reported 
to HDOH. We conducted prospective case-finding from September 30, 2013, 
through December 5, 2013, at which point we ceased surveillance given the most 
recent illness onset date of November 3, 2013.
2. MedWatch — FDA MedWatch is a system for consumers, patients, and 
healthcare providers to report adverse events associated with a variety of 
products, including medications, medical devices, and supplements.[11] FDA 
searched MedWatch for reports of adverse health effects associated with 
OxyELITE Pro™ and collected medical records for select patients for which a 
description of liver disease was provided, along with a history of OxyELITE 
Pro™ ingestion. For this analysis we included cases reported between April 1, 
2013, and December 5, 2013.
3. National call for cases — We requested cases through a Health Alert Network 
advisory distributed to state and local health departments, clinicians, and public 
health laboratories on October 8, 2013, and a short communication in CDC’s 
Morbidity and Mortality Weekly Report (MMWR) on October 10, 2013.[12,13] 
The Health Alert Network advisory and MMWR described the preliminary 
results of the investigation, including that the majority of patients identified had 
consumed OxyELITE Pro™, and requested that clinicians report patients 
meeting the case definition to their local or state health department and FDA 
MedWatch. We also sent a call for cases to the American Association for the 
Study of Liver Diseases (AASLD) and the United Network for Organ Sharing 
(UNOS). To facilitate case reports, CDC established a hotline for healthcare 
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providers to report cases of acute hepatitis of unknown etiology associated with 
consumption of a weight loss or muscle building dietary supplement through 
December 5, 2013.
4. DoD case finding — Given the prevalence of dietary supplement use among 
active duty military personnel, DoD performed active surveillance for cases by 
using the Defense Medical Surveillance System (DMSS), which is maintained by 
the Armed Forces Health Surveillance Center (AFHSC).[14,15] The DMSS was 
used to identify a cohort of U.S. active duty military personnel and other 
beneficiaries who had ALT and total bilirubin values consistent with the case 
definition and had an ICD-9 diagnosis of acute or unspecified hepatitis from 
April 1, 2013, through December 5, 2013. Potential cases were excluded if they 
had a diagnosis or laboratory evidence of viral, bacterial, or pre-existing chronic 
hepatitis. DoD personnel then contacted these individuals to determine whether 
they had exposure to a dietary supplement marketed for weight loss or muscle 
building or had any previous medical history that would exclude them as a case. 
In addition, each service put out a call for cases through their public health 
centers asking for any case of liver injury without a clear etiology.
Individuals meeting the case definition were administered a questionnaire which focused on 
demographics; presence and timing of signs and symptoms; previous medical history; any 
use of prescription drugs, over-the-counter medications, and dietary supplements in the 60 
days prior to illness onset; risk factors for liver injury (e.g., Tylenol [acetaminophen] and 
ethanol use) in the 60 days prior to illness onset; and outcomes including hospitalization, 
liver transplantation, and death. DoD personnel administered a modified version of the 
questionnaire that included DoD-specific questions. We standardized race according to U.S. 
Census categories and categorized case-patients into the following groups — Pacific 
Islander, Asian, white, multiple races, and other. We asked case-patients specifically about 
consumption of OxyELITE Pro™ as well as all other supplements. Information on 
supplement use included supplement name, serving sizes and frequency, dates of use, 
reasons for use, and locations of purchase. For case-patients with available medical charts, 
we abstracted results for autoimmune markers and peak laboratory values associated with 
liver injury. We reviewed case reports from the different data sources and identified potential 
duplicate reports based on demographic data. We then compared the data in these potential 
duplicates, rectified any discrepancies, and confirmed the final data with the state health 
departments and DoD.
We entered data from the questionnaire and chart abstraction into a Microsoft Excel 
database and calculated frequencies and proportions of reported values and responses using 
SAS version 9.3 (SAS Institute, Cary, NC).
Results
Case reporting
We received 86 possible case reports: 40 met the case definition; 27 did not meet the case 
definition; and 19 did not have enough information to determine their case status. The 40 
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case-patients lived in 23 states and two military bases outside the United States (Fig. 1). 
Case-patients were identified through the DoD (n = 21; 52.5%), NPDS (n = 7; 17.5%), FDA 
MedWatch (n = 7; 17.5%), state or local health departments (n = 3; 7.5%), transplant 
specialists (n = 1; 2.5%), and the CDC hotline (n = 1; 2.5%). Seven (17.5%) of the 40 case-
patients had questionnaire and medical chart data; an additional 30 (75.0%) case-patients 
had either medical chart or questionnaire data, and three (7.5%) case-patients had basic data 
collected from the case report form (Table 1).
Demographics and presenting illness
Mean age of the 40 case-patients was 33.9 years, with a range of 20–51 years. Twenty-four 
(60.0%) of the 40 case-patients were male. Thirty-five of the 40 case-patients reported a 
race, most commonly white (n = 15; 42.9%), Asian (n = 9; 25.7%), and Pacific Islander (n = 
5; 14.3%) (Table 2). The median body mass index (BMI) for the 32 case-patients with 
available data was 28.0 kg/m2 (range: 20.6–43.1); 26 (81.3%) case-patients were categorized 
as overweight or obese. Illness onset dates, which were available for 38 case-patients, ranged 
from April 10, 2013, through November 3, 2013 (Fig. 2). The most commonly reported 
signs and symptoms included jaundice or scleral icterus, fatigue, dark urine, nausea, and 
light- or clay-colored stools (Table 2).
Exposure to OxyELITE Pro™, alcohol, and medications
Twenty-five (62.5%) of 40 case-patients reported consuming OxyELITE Pro™ whereas 15 
(37.5%) reported consuming only another dietary supplement in the 60 days prior to illness 
onset. Of the 25 case-patients who consumed OxyELITE Pro™, nearly half (n = 12; 48%) 
consumed at least one other supplement, and greater than a quarter (n = 7; 28%) consumed 
only OxyELITE Pro™ and no other supplements (Table 3). Five of the 6 cases with 
incomplete information on supplement use were identified through NPDS or FDA 
MedWatch. No additional supplements were reported in common among the 12 case-
patients who consumed OxyELITE Pro™ and another dietary supplement. Of the 15 case-
patients who did not consume OxyELITE Pro™, three consumed C4™, two consumed NO-
Xplode™, and ten consumed some other weight loss or muscle building supplement. One 
case-patient who was originally reported to a poison center due to exposure to OxyELITE 
Pro™ subsequently reported consuming only another dietary supplement instead of 
OxyELITE Pro™.
Among the 25 case-patients exposed to OxyELITE Pro™, 17 provided a reason for use: 10 
(58.8%) to lose weight; four (23.5%) to improve athletic performance; two (11.8%) to 
increase energy; and one (5.9%) to increase muscle mass. For the 17 case-patients who 
reported their serving size, all consumed from one to three tablets or scoops per day, which 
was consistent with manufacturer recommendations. For the 19 case-patients who could 
remember when they started consuming OxyELITE Pro™, the median duration of 
OxyELITE Pro™ use prior to illness onset was 55 days (range:2–477 days).
Twenty-three (71.9%) of 32 case-patients with available data reported drinking any alcohol 
in the two months before illness onset. Twelve (66.7%) of 18 case-patients reported 
consuming two or fewer servings of alcohol at each sitting. Of the 12 case-patients who used 
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a prescription or over-the-counter medication in the two months prior to illness onset, two 
(16.7%) reported taking acetaminophen “a few times a month,” and one (8.3%) reported 
taking ibuprofen “a few times per week.”
Laboratory Data
Median laboratory values at the peak of illness are presented in Table 2, with markedly 
elevated AST, ALT, and total bilirubin levels. Two (25%) of the eight case-patients tested for 
antinuclear antibody (ANA) had positive tests and one of five (20%) tested for anti-smooth 
muscle antibody had a positive test. One of three case-patients (33%) tested for F-actin 
antibody had a positive test and another (33%) had a weakly positive test. One of five (20%) 
case-patients tested for anti-mitochondrial antibody had positive tests and both case-patients 
tested for anti-liver kidney microsomal antibody had negative tests. Twelve (63%) of 19 
case-patients with available data required a liver biopsy. For the three case-patients with liver 
biopsy data available, two (67%) had histopathological changes compatible with drug-
induced liver injury and autoimmune features and one (33%) case-patient had non-specific 
findings.
Hospitalization and Outcome
Twenty-six (70.3%) of 37 case-patients with available data and 17 (77.3%) of 22 patients 
exposed to OxyELITE Pro™ with available data were hospitalized. Three (27.3%) of 11 
case-patients with available data received N-acetylcysteine and four (36.4%) of 11 case-
patients with available data received corticosteroids. Of the 25 patients exposed to 
OxyELITE Pro™, 1 (5.9%) of 17 with available data received a liver transplant. No case-
patients died.
Discussion
Forty case-patients, including 25 case-patients who consumed OxyELITE Pro™, in 23 states 
and two military bases outside the United States developed acute hepatitis between April 1, 
2013, and December 5, 2013 following consumption of a weight loss or sports dietary 
supplement. Viral hepatitis panels were reported to be negative for each case-patient, and 
case-patients did not report risk factors such as routine acetaminophen use in the 60 days 
prior to illness onset. This investigation (40 total case-patients; 25 consumed OxyELITE 
Pro™) and the Hawaii investigation (52 total case-patients; 44 consumed OxyELITE Pro™) 
identified a combined total of 92 case-patients, of whom 69 consumed OxyELITE Pro™.[9] 
Of these 69 case-patients who consumed OxyELITE Pro™, 32 required hospitalization, 3 
required liver transplants, and 1 died.
Prior to our investigation, FDA had received reports of acute adverse health effects 
associated with the use of a formulation of OxyELITE Pro™ containing 1,3-
dimethylamylamine (DMAA).[16] A study published in 2014 documented acute liver injury 
in seven active duty service members who had consumed a formulation of OxyELITE Pro™ 
labeled as containing DMAA.[17] The manufacturer released a DMAA-free formulation of 
OxyELITE Pro™ that included aegeline in early 2013.[18] After FDA notified the 
manufacturer that it had failed to inform FDA of the use of aegeline, which was determined 
Chatham-Stephens et al. Page 6
Drug Test Anal. Author manuscript; available in PMC 2018 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
to be a new dietary ingredient, the manufacturer recalled aegeline-containing formulations of 
OxyELITE Pro™ in November 2013.
Dietary supplements and medications associated with liver injury appear to do so through 
two main mechanisms: either a predictable, dose-dependent toxic effect from a medication 
(e.g., acetaminophen) or a less predictable, immuno-allergic, idiosyncratic reaction to an 
ingredient of the product.[19] Although the exact incidence of liver injury associated with 
dietary supplements is unknown, a prospective study of drug-induced liver injury identified 
dietary supplements as the cause of liver injury in 130 (15.5%) of 839 consecutively enrolled 
patients.[5]
Drug- or herb-induced liver injury can be a difficult diagnosis given the absence of safety 
data on many ingredients contained in these products; the presence of co-exposures 
potentially associated with liver injury including medications, supplements, and alcohol; 
interactions among the multiple ingredients in products and drugs; and the lack of a 
definitive laboratory test for drug-induced liver injury. Although several clinical diagnostic 
criteria have been published, there is no standardized algorithm to diagnose drug-induced 
liver injury.[7] Instead, the diagnosis is one of exclusion —it relies on a temporal association 
of exposure followed by the development of signs and symptoms, and more importantly, the 
exclusion of other causes of liver injury.[7,20] Therefore, in this investigation we chose a 
specific case definition to exclude other causes of liver injury such as viral hepatitis; pre-
existing autoimmune hepatitis; chronic alcohol use; and chronic liver diseases.
Since dietary supplements often contain multiple ingredients, some with unknown safety 
profiles and most with unknown interactions, determining the etiologic agent and 
mechanism of liver injury associated with these products is difficult. A single, definitive 
etiologic agent is not typically identified in investigations of liver injury associated with a 
supplement.[21,22] As part of the Hawaii investigation, FDA performed both a general 
analytic laboratory screen and targeted testing of OxyELITE Pro™ for potentially 
hepatotoxic agents.[9,18] The testing confirmed the ingredients listed on the label and did not 
identify any known hepatotoxic agents, so the specific causative ingredient remains 
unknown. The absence of a known hepatotoxic agent identified on testing may suggest 
either the presence of a less common hepatotoxic agent that was not tested for, an 
idiosyncratic reaction to one of the listed ingredients, or a reaction to the combination of 
ingredients in the product. In addition to the product testing, FDA performed a trace back of 
OxyELITE Pro™ but did not identify a unique lot common to case-patients in the Hawaii 
investigation.[9,18] Compared to the Hawaii investigation, where 52 case-patients were 
identified, we identified 40 case-patients in several states, with California being the only 
state with more than 3 cases. The reason for this apparent clustering of case-patients in 
Hawaii without any clustering of case-patients in the continental United States remains 
unclear.
Our investigation demonstrated characteristics consistent with previous reports of drug-
induced liver injury. In a prospective study of 839 consecutively enrolled patients with 
suspected drug-induced liver injury, 60% of patients were female and the median duration of 
supplement use was 30 days for non-bodybuilding supplements and 43.5 days for 
Chatham-Stephens et al. Page 7
Drug Test Anal. Author manuscript; available in PMC 2018 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
bodybuilding supplements.[5] In our investigation 40% of the patients were female and the 
median duration of supplement use was 55 days. Similar to our investigation and the 
investigation in Hawaii, case-patients in some prior investigations of drug- or herb-induced 
liver injury reported consuming the serving sizes recommended by the manufacturers.[23,24] 
The increases in ALT, AST, and total bilirubin with only a borderline elevation in alkaline 
phosphatase observed in our investigation suggest a hepatocellular pattern of liver injury, 
which is often observed in drug- or herb-induced liver injury.[4,25]
In our study, 25.7% of the 35 individuals with available race data reported Asian as their 
race compared to 4.8% of the 2010 U.S. population.[26] In a previous study of idiosyncratic 
drug-induced liver injury, Asians were also over-represented, comprising 6.8% of the case-
patients compared to 3.6% of the 2000 U.S. population.[25] Whether this racial distribution 
can be attributed to purchasing practices, genetic differences suggesting that Asians may be 
at higher risk for drug-induced liver injury, cultural practices placing Asians at higher risk 
for exposure to a hepatotoxic agent, or some other unidentified factor remains unclear. A 
nationally representative survey documented that individuals from multiple races and Asians 
had the highest rates of dietary supplement use, with 24.6% of Asians reporting supplement 
use.[27] In a prospective study of 660 patients diagnosed with drug-induced liver injury by 
the Drug Induced Liver Injury Network, Asian race was a risk factor for both liver 
transplantation and death within six months of diagnosis. The reason for this finding is 
unclear, but the authors postulate that Asians may: 1) have greater susceptibility to drug-
induced liver injury; 2) present later in the course of illness; or 3) have impaired liver 
regeneration.[28]
The significance of the positive autoimmune antibodies in some of our case-patients is also 
unclear. Prior studies have documented autoimmune antibodies such as ANA in cases of 
drug-induced liver injury. A prospective, multi-center study in the United States documented 
that 19 (24%) of 79 case-patients with drug-induced liver injury tested for autoimmune 
antibodies had positive tests.[25] In addition to drug-induced liver injury, these antibodies 
have been documented in all-cause liver failure, but have not been associated with a 
particular toxic etiology. Whether these antibodies serve a role in the immunoallergic 
pathogenesis underlying the idiosyncratic liver injury or if they are a consequence of the 
liver injury is uncertain.[25,29]
Since no specific surveillance system for drug-induced liver injury exists, we had to use 
multiple sources for case ascertainment. Three of these sources (NPDS, MedWatch, and the 
national call for cases) relied on voluntary reporting of cases. The Institute of Medicine 
estimates that less than half of all poisonings are reported to poison centers, so reports to 
poison centers may underestimate the true number of cases.[30] Our approach was subject to 
several limitations. Due to the lack of more generic codes or product terms, we searched 
NPDS using only the OxyELITE Pro™ product-specific code and FDA searched MedWatch 
for cases associated with only OxyELITE Pro™. Therefore, case-finding in NPDS and 
MedWatch was limited to those persons with exposure to OxyELITE Pro™. This inability to 
identify cases in NPDS and MedWatch with exposure to dietary supplements other than 
OxyELITE Pro™ resulted in an over-representation of OxyELITE Pro™ use among cases. 
The identification of cases associated with other dietary supplements may have yielded 
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additional information regarding risk factors for illness. Since information on dietary 
supplement product used was self-reported, individuals may have incorrectly identified or 
may not have remembered the supplement they were taking. We attempted to exclude the 
major causes of acute hepatitis (e.g., viral hepatitis, acetaminophen) through the case 
definition, questionnaire, and chart abstraction; however, in many cases, we did not have 
access to complete medical records which might have provided additional information about 
the cause of liver injury.
We based our case definition on the moderate severity grade developed by the Drug-Induced 
Liver Injury Network.[31] The strict case definition likely limited our investigation to those 
case-patients more severely affected and underestimated the true number of cases. Another 
factor that potentially resulted in underreporting is that only an estimated 45% of U.S. adults 
who use dietary supplements report the products to their healthcare provider.[32] Therefore, 
if a patient presented to a healthcare provider with acute hepatitis of unknown etiology and 
that provider was unaware of the patient’s supplement use, the healthcare provider would be 
unable to report the patient as a case. Although none of the case-patients reported excessive 
alcohol or acetaminophen consumption, it cannot be determined as to whether their rates of 
use may have contributed to liver injury. In addition, the descriptive data in our analysis 
limited our ability to explore specific risk factors for developing acute hepatitis. The exact 
number of individuals who consume specific supplements, such as OxyELITE Pro™, and 
the incidence of supplement-induced liver injury are unknown. As such, we cannot quantify 
the baseline number of dietary supplement-induced liver injuries in the United States, nor 
can we determine for certain if the overall number of cases of acute hepatitis identified in 
this investigation is greater than what would be expected based on background incidence.
We recommend that clinicians and supplement users be aware of the potential for adverse 
health effects from using such products and report adverse health effects to FDA MedWatch, 
their local poison center, and/or their local or state department of health. We also 
recommend healthcare providers ask about supplement use during routine and sick visits, 
especially when evaluating acute hepatitis. We identified case reports through multiple 
sources, with NPDS and FDA MedWatch accounting for only 7 (17.5%) case reports each. 
Improving the ability to search surveillance systems like NPDS and FDA MedWatch for 
individual and grouped dietary supplements, as well as coordinating case-finding with DoD, 
may benefit ongoing surveillance efforts and future outbreak responses involving adverse 
health effects from dietary supplements. Due to the racial distribution observed in the case-
finding efforts in Hawaii and in our national case-finding efforts, federal agencies are 
developing ways to collaborate with their partners to explore many issues, including 
potential genetic components of drug-induced liver injury.
Conclusion
Through multiple sources, we identified 40 persons within the United States, excluding 
residents of Hawaii, who developed acute hepatitis between April 1, 2013, and December 5, 
2013 after consuming a weight loss or sports supplement. Of the 25 persons who reported 
consuming OxyELITE Pro™, 17 were hospitalized and 1 required a liver transplantation. 
No case-patients in our investigation died. Combining our results with the Hawaii 
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investigation, 69 case-patients consumed OxyELITE Pro™, of whom 32 required 
hospitalization, 3 required liver transplants and 1 died. Given that only approximately one-
third of case patients were identified by existing surveillance systems (NPDS and FDA 
MedWatch), improving the ability of these systems to detect cases associated with individual 
or groups of dietary supplements may benefit future outbreak investigations. Overall, this 
investigation highlights opportunities and challenges in using multiple sources to identify 
cases of suspected supplement associated adverse events. Surveillance and outbreak 
investigations involving dietary supplements should consider searching multiple data 
sources, including FDA MedWatch, DoD medical health records, and NPDS, for case 
reports.
Glossary
AASLD American Association for the Study of Liver Diseases
AFHSC Armed Forces Health Surveillance Center
ALT Alanine aminotransferase
ANA Antinuclear antibody
AST Aspartate aminotransferase
BMI Body mass index
CDC Centers for Disease Control and Prevention
DMSS Defense Medical Surveillance System
DoD Department of Defense
FDA Food and Drug Administration
HDOH Hawaii Department of Health
INR International normalized ratio
IU/L International units per liter
kg/m2 Kilogram/meter squared
mg/ dL Milligram/deciliter
MMWR Morbidity and Mortality Weekly Report
NPDS National Poison Data System
UNOS United Network for Organ Sharing
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Figure 1. 
State of Residence for Case-patients — United States, 2013, n = 40
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Figure 2. 
Reported Month of Symptom Onset for Case-patients — United States, 2013, n = 38
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Table 2
Demographics, presenting signs and symptoms, and laboratory tests for case-patients — United States, 2013*
All case-patients n (%) Case-patients exposed to OxyELITE Pro™ n (%)
Sex Male 24 (60.0) 10 (40.0)
Female 16 (40.0) 15 (60.0)
Race White 15 (42.9) 4 (20.0)
Asian 9 (25.7) 9 (45.0)
Pacific Islander 5 (14.3) 5 (25.0)
Black 3 (8.6) 0 (0.0)
Other 2 (5.7) 1 (5.0)
Multiple races 1 (2.9) 1 (5.0)
Signs and symptoms Jaundice 29 (90.6) 16 (94.1)
Fatigue 29 (87.9) 18 (100.0)
Dark urine 28 (84.9) 17 (94.4)
Nausea 24 (75.0) 14 (82.4)
Light- or clay-colored stools 22 (71.0) 13 (81.3)
Appetite loss 20 (62.5) 14 (82.4)
Abdominal pain 18 (54.6) 10 (55.6)
Laboratory Test Reference Range † Median Value (Range) Median Value (Range)
AST, IU/L  10–34 1,382 (138–2,525) 1,500 (853–2,525)
ALT, IU/L  10–40 1,597 (391–2,843) 1,849 (975–2,843)
Alkaline phosphatase, IU/L  44–147 166 (115–331) 166 (115–331)
Total bilirubin, mg/dL  0.3–1.9 6.7 (2.4–26.4) 6.1 (2.4–26.4)
INR  0.8–1.1 1.2 (0.8–3.8) 1.2 (1.0–3.8)
*
The number of case-patients who responded to each question varied
†
Reference ranges obtained from National Library of Medicine
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Table 3
Case-patients who Reported Consuming OxyELITE Pro™ by Source of Identification and Other Supplement 
Use — United States, 2013 (n = 25)
Identified through NPDS or 
FDA MedWatch n (%)
Identified by DoD, state health 
department, or CDC Hotline n (%)
Overall n (%)
Consumed only OxyELITE Pro™ 3 (23.1) 4 (33.3) 7 (28.0)
Consumed OxyELITE Pro™ and another 
supplement
5 (38.5) 7 (58.3) 12 (48.0)
Incomplete information on supplement use 
other than OxyELITE Pro™
5 (38.5) 1 (8.3) 6 (24.0)
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